JP2023506838A5 - - Google Patents

Info

Publication number
JP2023506838A5
JP2023506838A5 JP2022536658A JP2022536658A JP2023506838A5 JP 2023506838 A5 JP2023506838 A5 JP 2023506838A5 JP 2022536658 A JP2022536658 A JP 2022536658A JP 2022536658 A JP2022536658 A JP 2022536658A JP 2023506838 A5 JP2023506838 A5 JP 2023506838A5
Authority
JP
Japan
Prior art keywords
hydroxyl
pharmaceutical composition
neovascular
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022536658A
Other languages
English (en)
Japanese (ja)
Other versions
JP7831775B2 (ja
JP2023506838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/018475 external-priority patent/WO2021125800A1/ko
Publication of JP2023506838A publication Critical patent/JP2023506838A/ja
Publication of JP2023506838A5 publication Critical patent/JP2023506838A5/ja
Application granted granted Critical
Publication of JP7831775B2 publication Critical patent/JP7831775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022536658A 2019-12-16 2020-12-16 新生血管形成因子を阻害するための化合物およびその用途 Active JP7831775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190168238 2019-12-16
KR10-2019-0168238 2019-12-16
PCT/KR2020/018475 WO2021125800A1 (ko) 2019-12-16 2020-12-16 신생혈관형성인자의 억제를 위한 화합물 및 그 용도

Publications (3)

Publication Number Publication Date
JP2023506838A JP2023506838A (ja) 2023-02-20
JP2023506838A5 true JP2023506838A5 (cg-RX-API-DMAC7.html) 2023-12-20
JP7831775B2 JP7831775B2 (ja) 2026-03-17

Family

ID=76477859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022536658A Active JP7831775B2 (ja) 2019-12-16 2020-12-16 新生血管形成因子を阻害するための化合物およびその用途

Country Status (9)

Country Link
US (1) US12545695B2 (cg-RX-API-DMAC7.html)
EP (1) EP4079309A4 (cg-RX-API-DMAC7.html)
JP (1) JP7831775B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210076875A (cg-RX-API-DMAC7.html)
CN (1) CN114901290B (cg-RX-API-DMAC7.html)
AU (1) AU2020409912A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011147A2 (cg-RX-API-DMAC7.html)
CA (1) CA3164800A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021125800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164800A1 (en) 2019-12-16 2021-06-24 Unist(Ulsan National Institute Of Science And Technology) Compound for inhibiting neovascularization factors and use thereof
JP7766885B2 (ja) * 2021-06-15 2025-11-11 スマーティン バイオ インコーポレイテッド Trap1阻害剤およびその用途
KR20220167945A (ko) * 2021-06-15 2022-12-22 주식회사 스마틴바이오 Trap-1 억제제
IT202200008621A1 (it) * 2022-04-29 2023-10-29 Sifi Spa Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제
KR20260076808A (ko) 2024-11-20 2026-05-28 주식회사 스마틴바이오 Trap1 억제제를 포함하는 암 예방 또는 치료용 병용투여 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
DE69818675T2 (de) 1997-07-29 2004-07-29 Alcon Laboratories, Inc., Fort Worth Galaktomannanpolymere und borat enthaltende augenarzneimittel
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
KR20070030815A (ko) * 2004-07-13 2007-03-16 오리디스 비오메드 포르슝스-운트 엔트비크룽스 게엠베하 간질환 및 상피암의 치료에서 미토콘드리아적으로 표적화된산화방지제의 용도
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
WO2010121177A2 (en) 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
KR101621418B1 (ko) 2014-03-19 2016-05-23 울산과학기술원 미토콘드리아 표적화된 항-종양 조성물
CA3164800A1 (en) 2019-12-16 2021-06-24 Unist(Ulsan National Institute Of Science And Technology) Compound for inhibiting neovascularization factors and use thereof

Similar Documents

Publication Publication Date Title
RU2009145939A (ru) Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
JP2008538215A5 (cg-RX-API-DMAC7.html)
JP2020530470A5 (cg-RX-API-DMAC7.html)
JP2015025011A5 (cg-RX-API-DMAC7.html)
JP6872322B2 (ja) クエン酸エステルを含有するデポ剤
JP2006512318A5 (cg-RX-API-DMAC7.html)
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
JP2014533274A5 (cg-RX-API-DMAC7.html)
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP2017527600A5 (cg-RX-API-DMAC7.html)
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2024041947A (ja) 眼圧下降増強剤
JP2013510852A5 (cg-RX-API-DMAC7.html)
JP2010514733A5 (cg-RX-API-DMAC7.html)
WO2008124828A1 (en) Methods for treating vascular disruption disorders
JP2007527417A5 (cg-RX-API-DMAC7.html)
RU2020119228A (ru) Соединения, композиции и способы лечения нарушений со стороны органа зрения и заболеваний кожи
RU2012119757A (ru) 2, 6-диаминопиридиновые соединения для лечения заболеваний, связанных с амилоидными белками, или для лечения глазных болезней
JP2019534269A5 (cg-RX-API-DMAC7.html)
JP2022547231A5 (cg-RX-API-DMAC7.html)
JP2023531411A5 (cg-RX-API-DMAC7.html)
JP2022520832A5 (cg-RX-API-DMAC7.html)
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
JP2021138710A5 (cg-RX-API-DMAC7.html)
RU2019118904A (ru) Распределение в глазу и фармакокинетика композиций лифитеграста